 "Alembic Pharma gets USFDA nod for generic antidepressant drug")
Alembic Pharmaceuticals has received approval from the US health regulator for generic Fluoxetine Hydrochloride tablets used for the treatment of depression and panic disorder.
The approval is for the generic version of Eli Lilly and Company's Prozac tablets in the same strengths, Alembic Pharma said in a BSE filing today.
The tablets are indicated for treatment of major depressive disorder and obsessive compulsive disorder in adult and paediatric patients, it said.
They are also indicated for treatment of binge-eating and vomiting behaviour in moderate to severe Bulimia Nervosa and acute treatment of panic disorder, in adult patients.
"The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application for Fluoxetine Hydrochloride tablets, 10 mg and 20 mg", it said.
These tablets have an estimated market size of $120 million for 12 months ending December 2015 according to IMS, the company added.
Alembic Pharma currently has a total of 53 ANDA approvals from the US health regulator.
The company's stock was trading 0.84 per cent higher at Rs 625 per scrip on BSE today.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%